HomeCompareONTX vs BTI

ONTX vs BTI: Dividend Comparison 2026

ONTX yields 200.94% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ONTX wins by $122.63M in total portfolio value
10 years
ONTX
ONTX
● Live price
200.94%
Share price
$1.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$122.67M
Annual income
$61,985,799.78
Full ONTX calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — ONTX vs BTI

📍 ONTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodONTXBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ONTX + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ONTX pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ONTX
Annual income on $10K today (after 15% tax)
$17,080.28/yr
After 10yr DRIP, annual income (after tax)
$52,687,929.81/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, ONTX beats the other by $52,685,561.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ONTX + BTI for your $10,000?

ONTX: 50%BTI: 50%
100% BTI50/50100% ONTX
Portfolio after 10yr
$61.35M
Annual income
$30,994,293.21/yr
Blended yield
50.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

ONTX
Analyst Ratings
9
Buy
2
Hold
Consensus: Buy
Altman Z
-72.0
Piotroski
2/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ONTX buys
0
BTI buys
0
No recent congressional trades found for ONTX or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricONTXBTI
Forward yield200.94%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$122.67M$37.7K
Annual income after 10y$61,985,799.78$2,786.64
Total dividends collected$115.63M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: ONTX vs BTI ($10,000, DRIP)

YearONTX PortfolioONTX Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$30,794$20,094.44$11,299$598.92+$19.5KONTX
2$90,782$57,831.52$12,794$703.91+$78.0KONTX
3$256,469$159,333.15$14,518$829.07+$242.0KONTX
4$695,110$420,688.13$16,513$978.64+$678.6KONTX
5$1,809,369$1,065,601.15$18,827$1,157.84+$1.79MONTX
6$4,528,320$2,592,294.39$21,518$1,373.12+$4.51MONTX
7$10,908,621$6,063,318.62$24,657$1,632.46+$10.88MONTX
8$25,323,064$13,650,840.17$28,329$1,945.74+$25.29MONTX
9$56,711,380$29,615,701.55$32,637$2,325.33+$56.68MONTX
10$122,666,977$61,985,799.78$37,708$2,786.64+$122.63MONTX

ONTX vs BTI: Complete Analysis 2026

ONTXStock

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Full ONTX Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this ONTX vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ONTX vs SCHDONTX vs JEPIONTX vs OONTX vs KOONTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.